Galphimia glauca for Anxiety

Verdict: Promising but unconfirmed for generalized anxiety

Two double-blind RCTs suggest standardized Galphimia glauca may ease generalized anxiety about as well as lorazepam, but the evidence is weak: both trials come from a single Mexican research group with no independent replication, so it should not be treated as a proven anxiety treatment.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

The grade rests almost entirely on two moderate-quality, double-blind randomized trials of a standardized galphimine-B extract in generalized anxiety disorder. The first (PMID 17562493; n=152, 4 weeks) found the herb anxiolytically non-inferior to lorazepam from week one with better tolerability. The second (PMID 22828921; n=192, 15 weeks) reported a small effectiveness edge over lorazepam (0.686 vs 0.588, p=0.0003) without dependence or withdrawal.

Those are genuinely encouraging signals, but the evidence base is thin and fragile. Both trials were run by the same government-funded Mexican investigators, with no independent or multi-center replication, and the 15-week study lost nearly half its participants (191 enrolled, 104 completed), which weakens its superiority claim. There is no Cochrane review or independent meta-analysis, so the findings cannot yet be generalized.

No major regulator (FDA, EFSA, NHS, WHO) or clinical authority (NIH ODS, Mayo, Cleveland Clinic, Harvard, APA/ADAA) has evaluated or commented on it, which is typical for an obscure Mexican herb rather than a red flag. Lorazepam comparisons describe trial design only and do not make this a substitute for a prescription benzodiazepine; theoretical additive sedation with benzodiazepines, other CNS depressants, or serotonergic drugs is plausible, and there are no safety data in pregnancy, breastfeeding, or children.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
50%
Conflicting evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.436
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam
PMID: 17562493 2007 RCT (double-blind) n = 152
Finding: G. glauca showed anxiolytic effectiveness very similar (non-inferior) to lorazepam from week 1, with higher tolerability.
Government Effect size: [object Object]
View on PubMed
Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial
PMID: 22828921 2012 RCT (double-blind) n = 192
Finding: G. glauca was superior to lorazepam in effectiveness (0.686 vs 0.588, p=0.0003), with comparable tolerability and no dependence/withdrawal.
Government Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-galphimia-glauca-001 繁體中文版 →